Semaglutide

Semaglutide is a GLP-1 agonist that has been used in patients with type 2 diabetes control their blood sugar for many years. It is marketed by Novo Nordisk as an injection as the drug Ozempic® and as an oral tablet as Rybelsus®. The FDA recently approved a new use for the drug, allowing it to help patients battling chronic weight management. This is the same injectable drug but marketed by Novo Nordisk as Wegovy®.

The usage of GLP-1 receptor agonists has grown worldwide. Many patients would prefer to avoid injections if possible, and there is an extremely low absorption of oral tablets (less than 1% per the labeling for RYBELSUS®).

For these reasons, prescribers and patients may prefer a patent-pending compounded formulation of Semaglutide for sublingual administration described here.

Available with a prescription from a healthcare provider, this patent-pending compounded formulation was specifically developed to carry the very large molecule of Semaglutide through sublingually in the mucosal tissue of the mouth when held under the tongue for 90 seconds.

You can click here to download our guide to e-scribing Compounded Semaglutide to our pharmacy. You may wish to give his to your physician.

Call one of our pharmacists today to learn more about this patent-pending formulation of sub-lingual semaglutide.